94 related articles for article (PubMed ID: 22648037)
1. Understanding the effect of drug-resistant mutations of HIV-1 intasome on raltegravir action through molecular modeling study.
Xue W; Qi J; Yang Y; Jin X; Liu H; Yao X
Mol Biosyst; 2012 Aug; 8(8):2135-44. PubMed ID: 22648037
[TBL] [Abstract][Full Text] [Related]
2. Exploring the molecular mechanism of cross-resistance to HIV-1 integrase strand transfer inhibitors by molecular dynamics simulation and residue interaction network analysis.
Xue W; Jin X; Ning L; Wang M; Liu H; Yao X
J Chem Inf Model; 2013 Jan; 53(1):210-22. PubMed ID: 23231029
[TBL] [Abstract][Full Text] [Related]
3. Reduced HIV-1 integrase flexibility as a mechanism for raltegravir resistance.
Dewdney TG; Wang Y; Kovari IA; Reiter SJ; Kovari LC
J Struct Biol; 2013 Nov; 184(2):245-50. PubMed ID: 23891838
[TBL] [Abstract][Full Text] [Related]
4. Molecular mechanism of HIV-1 integrase-vDNA interactions and strand transfer inhibitor action: a molecular modeling perspective.
Xue W; Liu H; Yao X
J Comput Chem; 2012 Feb; 33(5):527-36. PubMed ID: 22144113
[TBL] [Abstract][Full Text] [Related]
5. HIV-1 IN alternative molecular recognition of DNA induced by raltegravir resistance mutations.
Mouscadet JF; Arora R; André J; Lambry JC; Delelis O; Malet I; Marcelin AG; Calvez V; Tchertanov L
J Mol Recognit; 2009; 22(6):480-94. PubMed ID: 19623602
[TBL] [Abstract][Full Text] [Related]
6. Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles.
Goethals O; Vos A; Van Ginderen M; Geluykens P; Smits V; Schols D; Hertogs K; Clayton R
Virology; 2010 Jul; 402(2):338-46. PubMed ID: 20421122
[TBL] [Abstract][Full Text] [Related]
7. Impact of resistance mutations on inhibitor binding to HIV-1 integrase.
Chen Q; Buolamwini JK; Smith JC; Li A; Xu Q; Cheng X; Wei D
J Chem Inf Model; 2013 Dec; 53(12):3297-307. PubMed ID: 24205814
[TBL] [Abstract][Full Text] [Related]
8. Characterization and structural analysis of HIV-1 integrase conservation.
Ceccherini-Silberstein F; Malet I; D'Arrigo R; Antinori A; Marcelin AG; Perno CF
AIDS Rev; 2009; 11(1):17-29. PubMed ID: 19290031
[TBL] [Abstract][Full Text] [Related]
9. Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption.
Canducci F; Barda B; Ceresola E; Spagnuolo V; Sampaolo M; Boeri E; Nozza S; Cossarin F; Galli A; Gianotti N; Castagna A; Lazzarin A; Clementi M
Clin Microbiol Infect; 2011 Jun; 17(6):928-34. PubMed ID: 20854427
[TBL] [Abstract][Full Text] [Related]
10. Early emergence of raltegravir resistance mutations in patients receiving HAART salvage regimens.
Baldanti F; Paolucci S; Gulminetti R; Brandolini M; Barbarini G; Maserati R
J Med Virol; 2010 Jan; 82(1):116-22. PubMed ID: 19950236
[TBL] [Abstract][Full Text] [Related]
11. Implications of HIV-1 M group polymorphisms on integrase inhibitor efficacy and resistance: genetic and structural in silico analyses.
Loizidou EZ; Kousiappa I; Zeinalipour-Yazdi CD; Van de Vijver DA; Kostrikis LG
Biochemistry; 2009 Jan; 48(1):4-6. PubMed ID: 19090674
[TBL] [Abstract][Full Text] [Related]
12. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
Malet I; Delelis O; Soulie C; Wirden M; Tchertanov L; Mottaz P; Peytavin G; Katlama C; Mouscadet JF; Calvez V; Marcelin AG
J Antimicrob Chemother; 2009 Apr; 63(4):795-804. PubMed ID: 19221102
[TBL] [Abstract][Full Text] [Related]
13. Raltegravir: the first HIV type 1 integrase inhibitor.
Hicks C; Gulick RM
Clin Infect Dis; 2009 Apr; 48(7):931-9. PubMed ID: 19231980
[TBL] [Abstract][Full Text] [Related]
14. Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets.
Arora R; de Beauchene IC; Polanski J; Laine E; Tchertanov L
J Mol Recognit; 2013 Sep; 26(9):383-401. PubMed ID: 23836466
[TBL] [Abstract][Full Text] [Related]
15. Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir.
Canducci F; Marinozzi MC; Sampaolo M; Boeri E; Spagnuolo V; Gianotti N; Castagna A; Paolucci S; Baldanti F; Lazzarin A; Clementi M
J Antimicrob Chemother; 2010 Mar; 65(3):425-33. PubMed ID: 20056687
[TBL] [Abstract][Full Text] [Related]
16. Stabilization of the integrase-DNA complex by Mg2+ ions and prediction of key residues for binding HIV-1 integrase inhibitors.
Miri L; Bouvier G; Kettani A; Mikou A; Wakrim L; Nilges M; Malliavin TE
Proteins; 2014 Mar; 82(3):466-78. PubMed ID: 24038133
[TBL] [Abstract][Full Text] [Related]
17. The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
Malet I; Fourati S; Charpentier C; Morand-Joubert L; Armenia D; Wirden M; Sayon S; Van Houtte M; Ceccherini-Silberstein F; Brun-Vézinet F; Perno CF; Descamps D; Capt A; Calvez V; Marcelin AG
J Antimicrob Chemother; 2011 Dec; 66(12):2827-30. PubMed ID: 21933786
[TBL] [Abstract][Full Text] [Related]
18. Mutation N155H in HIV-2 integrase confers high phenotypic resistance to raltegravir and impairs replication capacity.
Salgado M; Toro C; Simón A; Garrido C; Blanco F; Soriano V; Rodés B
J Clin Virol; 2009 Oct; 46(2):173-5. PubMed ID: 19625211
[TBL] [Abstract][Full Text] [Related]
19. Resistance to HIV-1 integrase inhibitors: A structural perspective.
Mouscadet JF; Delelis O; Marcelin AG; Tchertanov L
Drug Resist Updat; 2010; 13(4-5):139-50. PubMed ID: 20570551
[TBL] [Abstract][Full Text] [Related]
20. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection.
Cooper DA; Steigbigel RT; Gatell JM; Rockstroh JK; Katlama C; Yeni P; Lazzarin A; Clotet B; Kumar PN; Eron JE; Schechter M; Markowitz M; Loutfy MR; Lennox JL; Zhao J; Chen J; Ryan DM; Rhodes RR; Killar JA; Gilde LR; Strohmaier KM; Meibohm AR; Miller MD; Hazuda DJ; Nessly ML; DiNubile MJ; Isaacs RD; Teppler H; Nguyen BY;
N Engl J Med; 2008 Jul; 359(4):355-65. PubMed ID: 18650513
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
